Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIGUEL ANGEL ISLAS-OHLMAYER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1295917425
CMS profile
59223
Location
EDGEWOOD, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$9,564.87

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIGUEL ANGEL ISLAS-OHLMAYER

NPI 1295917425 · CMS profile ID 59223

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

EDGEWOOD, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295917425?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295917425?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295917425?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1295917425?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $9,564.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $1,387.5012/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736013554 CMS
Seagen Inc. $15.8812/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732461093 CMS
Rigel Pharmaceuticals, Inc. $500.0011/23/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752093287 CMS
Rigel Pharmaceuticals, Inc. $1,750.0010/26/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752094683 CMS
Rigel Pharmaceuticals, Inc. $1,000.0010/01/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752092707 CMS
Rigel Pharmaceuticals, Inc. $1,900.0008/18/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752090287 CMS
GlaxoSmithKline, LLC. $17.6308/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738734653 CMS
Epizyme, Inc., $1,350.0007/29/2020 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748602959 CMS
Daiichi Sankyo Inc. $15.2407/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739494259 CMS
Global Blood Therapeutics, Inc. $11.0507/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742105037 CMS
Incyte Corporation $13.8607/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745790625 CMS
Eisai Inc. $16.3006/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751342571 CMS
Puma Biotechnology, Inc. $14.8806/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750542945 CMS
Pharmacyclics LLC, An AbbVie Company $13.9206/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725665013 CMS
Seagen Inc. $13.0806/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732460993 CMS
Rigel Pharmaceuticals, Inc. $125.0002/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752088721 CMS
Rigel Pharmaceuticals, Inc. $60.0002/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752088777 CMS
Rigel Pharmaceuticals, Inc. $698.3402/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752088783 CMS
Rigel Pharmaceuticals, Inc. $50.0002/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752089011 CMS
Rigel Pharmaceuticals, Inc. $551.8002/29/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752089271 CMS
Jazz Pharmaceuticals Inc. $23.1102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744452735 CMS
Jazz Pharmaceuticals Inc. $18.1401/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744452733 CMS
Aurobindo Pharma USA, Inc. $19.1401/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753058297 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,766.15 80
PY2020 $9,564.87 23
PY2021 $13,658.96 17
PY2022 $10,243.37 22
PY2023 $23,259.49 27
PY2024 $7,439.87 6
PY2025 $24,227.38 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $395.50 1
PY2025 Principal investigator $58,459.40 2
PY2024 Recipient $1,306.60 1
PY2024 Principal investigator $113,571.67 2
PY2023 Recipient $168.05 1
PY2023 Principal investigator $315,531.55 45
PY2022 Principal investigator $368,128.77 124
PY2021 Principal investigator $257,202.74 115
PY2020 Principal investigator $150,989.86 62
PY2019 Recipient $7,317.30 2
PY2019 Principal investigator $200,492.20 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $58.00 12/31/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 965539771
Principal investigator 1 TG Therapeutics, Inc. $426.30 12/31/2022 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938735511
Principal investigator 1 TG Therapeutics, Inc. $426.30 12/31/2022 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938735519
Principal investigator 1 TG Therapeutics, Inc. $550.00 12/30/2022 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938735513
Principal investigator 1 TG Therapeutics, Inc. $3,825.00 12/30/2022 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938735515
Principal investigator 1 TG Therapeutics, Inc. $550.00 12/30/2022 Non-covered Recipient Entity
Oncology Hematology Care Clinical Trials
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938735517
Principal investigator 1 ADC Therapeutics America, Inc. $9,001.00 12/27/2022 Non-covered Recipient Entity
US Oncology Research, LLC
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 960375493
Principal investigator 1 ADC Therapeutics America, Inc. $8,500.00 12/27/2022 Non-covered Recipient Entity
US Oncology Research, LLC
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) No dispute reported 06/30/2026 960375499
Principal investigator 1 Seagen Inc. $250.00 12/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902887
Principal investigator 1 Seagen Inc. $3,827.00 11/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902875
Principal investigator 1 Genentech, Inc. $2,338.00 10/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
POLARIX No dispute reported 06/30/2026 950693187
Principal investigator 1 MorphoSys AG $956.00 10/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397441
Principal investigator 1 MorphoSys AG $312.00 10/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397443
Principal investigator 1 Seagen Inc. $956.00 10/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917902669
Principal investigator 1 Seagen Inc. $956.00 10/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917903099
Principal investigator 1 Seagen Inc. $956.00 10/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917903105
Principal investigator 1 Incyte Corporation $30,145.80 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 905223157
Principal investigator 1 MorphoSys AG $150.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397431
Principal investigator 1 MorphoSys AG $150.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397439
Principal investigator 1 Seagen Inc. $718.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902179
Principal investigator 1 Seagen Inc. $589.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902185
Principal investigator 1 Seagen Inc. $150.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902193
Principal investigator 1 Seagen Inc. $150.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902315
Principal investigator 1 Seagen Inc. $589.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902327
Principal investigator 1 Seagen Inc. $150.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902345
Principal investigator 1 Seagen Inc. $589.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902357
Principal investigator 1 Seagen Inc. $150.00 09/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902363
Principal investigator 1 MorphoSys AG $250.00 08/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397425
Principal investigator 1 MorphoSys AG $150.00 08/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397427
Principal investigator 1 MorphoSys AG $2,081.00 08/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397429
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,200.00 08/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237673
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,200.00 08/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237679
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,200.00 08/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237681
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,200.00 08/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237683
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,250.00 08/03/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237537
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,250.00 08/03/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237545
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,250.00 08/03/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237547
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,250.00 08/03/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237549
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,250.00 08/03/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237551
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $2,159.14 07/27/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890237485
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397419
Principal investigator 1 MorphoSys AG $956.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397421
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397433
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397435
Principal investigator 1 MorphoSys AG $1,600.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397437
Principal investigator 1 Seagen Inc. $150.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901997
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902015
Principal investigator 1 Seagen Inc. $127.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902021
Principal investigator 1 Seagen Inc. $956.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902027
Principal investigator 1 Seagen Inc. $60.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902045
Principal investigator 1 Seagen Inc. $589.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902051
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902081
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902087
Principal investigator 1 Seagen Inc. $400.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902403
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902413
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902419
Principal investigator 1 Seagen Inc. $127.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902431
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902437
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902443
Principal investigator 1 Seagen Inc. $956.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902449
Principal investigator 1 Seagen Inc. $127.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902459
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902471
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902477
Principal investigator 1 Seagen Inc. $956.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917902483
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902489
Principal investigator 1 Seagen Inc. $2,211.00 07/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917902495
Principal investigator 1 Seagen Inc. $234.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901679
Principal investigator 1 Seagen Inc. $1,856.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901691
Principal investigator 1 Seagen Inc. $795.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901697
Principal investigator 1 Seagen Inc. $4,088.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901703
Principal investigator 1 Seagen Inc. $25.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901713
Principal investigator 1 Seagen Inc. $718.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901725
Principal investigator 1 Seagen Inc. $59.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901737
Principal investigator 1 Seagen Inc. $530.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901743
Principal investigator 1 Seagen Inc. $200.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901749
Principal investigator 1 Seagen Inc. $150.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901775
Principal investigator 1 Seagen Inc. $33.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901781
Principal investigator 1 Seagen Inc. $31.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901787
Principal investigator 1 Seagen Inc. $1,650.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901799
Principal investigator 1 Seagen Inc. $40.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901805
Principal investigator 1 Seagen Inc. $718.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901957
Principal investigator 1 Seagen Inc. $150.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901973
Principal investigator 1 Seagen Inc. $40.00 06/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901979
Principal investigator 1 Seagen Inc. $27,825.00 06/01/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902813
Principal investigator 1 Seagen Inc. $27,825.00 05/17/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917902807
Principal investigator 1 Seagen Inc. $2,211.00 05/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901657
Principal investigator 1 Seagen Inc. $2,211.00 05/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901939
Principal investigator 1 Seagen Inc. $2,211.00 05/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901945
Principal investigator 1 Seagen Inc. $2,211.00 05/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901951
Principal investigator 1 Genentech, Inc. $1,375.00 05/05/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
POLARIX No dispute reported 06/30/2026 950738293
Principal investigator 1 Genentech, Inc. $1,375.00 05/05/2022 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
POLARIX No dispute reported 06/30/2026 950738299
Principal investigator 1 Genentech, Inc. $2,338.00 04/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
POLARIX No dispute reported 06/30/2026 950729623
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,063.00 04/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma No dispute reported 06/30/2026 890236569
Principal investigator 1 Seagen Inc. $956.00 04/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917901627
Principal investigator 1 Seagen Inc. $956.00 04/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901915
Principal investigator 1 Seagen Inc. $956.00 04/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901921
Principal investigator 1 TG Therapeutics, Inc. $700.00 04/01/2022 Non-covered Recipient Entity
US Oncology Research, LLC
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938733055
Principal investigator 1 TG Therapeutics, Inc. $500.00 04/01/2022 Non-covered Recipient Entity
US Oncology Research, LLC
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma No dispute reported 06/30/2026 938733293
Principal investigator 1 TG Therapeutics, Inc. $500.00 04/01/2022 Non-covered Recipient Entity
US Oncology Research, LLC
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma No dispute reported 06/30/2026 938733295
Principal investigator 1 TG Therapeutics, Inc. $700.00 04/01/2022 Non-covered Recipient Entity
US Oncology Research, LLC
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938733477
Principal investigator 1 PFIZER INC. $17,497.73 03/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED ACTIVECOMPARATOR MULTICENTER PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN OR PLACEBO IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE BCELL LYMPHOMA DLBCL No dispute reported 06/30/2026 1130864797
Principal investigator 1 Seagen Inc. $589.00 03/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901595
Principal investigator 1 Seagen Inc. $150.00 03/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901605
Principal investigator 1 Seagen Inc. $250.00 03/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901611
Principal investigator 1 Seagen Inc. $589.00 03/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901887
Principal investigator 1 Seagen Inc. $150.00 03/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901893
Principal investigator 1 Celgene Corporation $9,420.00 02/15/2022 Non-covered Recipient Entity
Ohc Mercy West
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma No dispute reported 06/30/2026 937186311
Principal investigator 2 Celgene Corporation $109,674.50 02/01/2022 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 3B Randomized Study of Lenalidomide (CC-50 No dispute reported 06/30/2026 937183965
Principal investigator 1 TG Therapeutics, Inc. $450.00 01/31/2022 Non-covered Recipient Entity
US Oncology Research, LLC
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938733059
Principal investigator 1 TG Therapeutics, Inc. $450.00 01/31/2022 Non-covered Recipient Entity
US Oncology Research, LLC
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 938733479
Principal investigator 1 Incyte Corporation $1,125.00 01/24/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 905223111
Principal investigator 1 Incyte Corporation $956.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE, INC.
A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 No dispute reported 06/30/2026 905223135
Principal investigator 1 MorphoSys AG $956.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind No dispute reported 06/30/2026 954397377
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $1,063.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
Study of Ibrutinib and Rituximab in Treatment Nave Follicular Lymphoma No dispute reported 06/30/2026 890235949
Principal investigator 1 Seagen Inc. $2,211.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901552
Principal investigator 1 Seagen Inc. $2,211.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901829
Principal investigator 1 Seagen Inc. $2,211.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901835
Principal investigator 1 Seagen Inc. $956.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901847
Principal investigator 1 Seagen Inc. $956.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression No dispute reported 06/30/2026 917901853
Principal investigator 1 Seagen Inc. $2,211.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901859
Principal investigator 1 Seagen Inc. $956.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) No dispute reported 06/30/2026 917901863
Principal investigator 1 Seagen Inc. $2,211.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901869
Principal investigator 1 Seagen Inc. $2,211.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901985
Principal investigator 1 Seagen Inc. $2,211.00 01/15/2022 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD No dispute reported 06/30/2026 917901991